Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐CVAD in relapsed/refractory acute lymphocytic leukaemia
暂无分享，去创建一个
H. Kantarjian | G. Garcia-Manero | F. Ravandi | G. Borthakur | E. Jabbour | S. O'brien | Deborah A. Thomas | Hui Yang | M. Rytting | C. Benton | A. Franklin | M. Kwari | S. Dara | S. Pierce | D. Thomas | Christopher B. Benton